Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048116458> ?p ?o ?g. }
- W3048116458 endingPage "447" @default.
- W3048116458 startingPage "447" @default.
- W3048116458 abstract "Advanced hepatocellular carcinoma has limited treatment options, but there has been extensive growth recently with cabozantinib, regorafenib, lenvatinib, nivolumab, atezolizumab, and bevacizumab, which are some of the treatments that have received FDA approval just over the last three years. Because HCC tumor microenvironment is potentially immunogenic and typically characterized by inflammation, immunotherapy has been proposed as a potential novel therapeutic approach, which has prompted studies in advanced HCC patients investigating various immune-therapeutic strategies such as CAR-T cell therapy, checkpoint inhibitors, and onco-vaccines. The anti-PD-1 checkpoint inhibitors nivolumab and pembrolizumab have been FDA approved as a second line treatment in patients who progressed or are intolerant to Sorafenib. To build up on the success of PD-1 monotherapy, combinatorial regimens with PD-1/PD-L1 inhibitors plus VEGF targeted agents have shown positive results in various malignancies including HCC. The combination of atezolizumab plus bevacizumab is the new addition to the HCC treatment armamentarium following a pivotal study that demonstrated an improvement in OS over frontline sorafenib. Other novel immune-based approaches and oncolytic viruses are in the early phases of clinical evaluation. These innovative approaches enhance the intensity of cancer-directed immune responses and will potentially impact the outlook of this aggressive disease." @default.
- W3048116458 created "2020-08-13" @default.
- W3048116458 creator A5001854462 @default.
- W3048116458 creator A5008564726 @default.
- W3048116458 creator A5048681236 @default.
- W3048116458 creator A5057978746 @default.
- W3048116458 creator A5060310347 @default.
- W3048116458 date "2020-08-08" @default.
- W3048116458 modified "2023-10-06" @default.
- W3048116458 title "Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma" @default.
- W3048116458 cites W1971837077 @default.
- W3048116458 cites W1983517349 @default.
- W3048116458 cites W1986839314 @default.
- W3048116458 cites W1999673890 @default.
- W3048116458 cites W2001131198 @default.
- W3048116458 cites W2005484337 @default.
- W3048116458 cites W2012972418 @default.
- W3048116458 cites W2013394982 @default.
- W3048116458 cites W2046000826 @default.
- W3048116458 cites W2061499228 @default.
- W3048116458 cites W2072773155 @default.
- W3048116458 cites W2079990421 @default.
- W3048116458 cites W2082751482 @default.
- W3048116458 cites W2093059993 @default.
- W3048116458 cites W2102724983 @default.
- W3048116458 cites W2120165383 @default.
- W3048116458 cites W2122222213 @default.
- W3048116458 cites W2128965737 @default.
- W3048116458 cites W2133402546 @default.
- W3048116458 cites W2140587309 @default.
- W3048116458 cites W2156383220 @default.
- W3048116458 cites W2156906256 @default.
- W3048116458 cites W2179055275 @default.
- W3048116458 cites W2194546364 @default.
- W3048116458 cites W2228442267 @default.
- W3048116458 cites W2286120012 @default.
- W3048116458 cites W2410319265 @default.
- W3048116458 cites W2430957119 @default.
- W3048116458 cites W2505737634 @default.
- W3048116458 cites W2508545091 @default.
- W3048116458 cites W2511951051 @default.
- W3048116458 cites W2561100838 @default.
- W3048116458 cites W2562740476 @default.
- W3048116458 cites W2566205030 @default.
- W3048116458 cites W2567441703 @default.
- W3048116458 cites W2570331434 @default.
- W3048116458 cites W2591245792 @default.
- W3048116458 cites W2602027164 @default.
- W3048116458 cites W2604405073 @default.
- W3048116458 cites W2605532397 @default.
- W3048116458 cites W2606367731 @default.
- W3048116458 cites W2610302449 @default.
- W3048116458 cites W2618174085 @default.
- W3048116458 cites W2621587943 @default.
- W3048116458 cites W2622499649 @default.
- W3048116458 cites W2735359378 @default.
- W3048116458 cites W2736137548 @default.
- W3048116458 cites W2753432434 @default.
- W3048116458 cites W2775356055 @default.
- W3048116458 cites W2791034227 @default.
- W3048116458 cites W2792937256 @default.
- W3048116458 cites W2794577178 @default.
- W3048116458 cites W2800383218 @default.
- W3048116458 cites W2801641802 @default.
- W3048116458 cites W2887992554 @default.
- W3048116458 cites W2892757136 @default.
- W3048116458 cites W2900046418 @default.
- W3048116458 cites W2910806811 @default.
- W3048116458 cites W2911526204 @default.
- W3048116458 cites W2913515510 @default.
- W3048116458 cites W2914098003 @default.
- W3048116458 cites W2937354878 @default.
- W3048116458 cites W2941890769 @default.
- W3048116458 cites W2942775665 @default.
- W3048116458 cites W2945606195 @default.
- W3048116458 cites W2947829857 @default.
- W3048116458 cites W2955678947 @default.
- W3048116458 cites W2967121126 @default.
- W3048116458 cites W2976744492 @default.
- W3048116458 cites W2977722669 @default.
- W3048116458 cites W2990602950 @default.
- W3048116458 cites W2999031113 @default.
- W3048116458 cites W3004517814 @default.
- W3048116458 cites W3005265102 @default.
- W3048116458 cites W3007966471 @default.
- W3048116458 cites W3025022288 @default.
- W3048116458 cites W3027392290 @default.
- W3048116458 cites W3031070321 @default.
- W3048116458 cites W3038041373 @default.
- W3048116458 cites W3043703771 @default.
- W3048116458 cites W3045528039 @default.
- W3048116458 cites W4211197244 @default.
- W3048116458 cites W4238423864 @default.
- W3048116458 doi "https://doi.org/10.3390/vaccines8030447" @default.
- W3048116458 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7563532" @default.
- W3048116458 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32784389" @default.
- W3048116458 hasPublicationYear "2020" @default.
- W3048116458 type Work @default.